Motivation: There is unmet need for noninvasive biomarkers for neoadjuvant immunochemotherapy (NICT) response prediction in triple negative breast cancer (TNBC) to guide least toxic and most effective treatment regimens. Goal(s): To evaluate if DCE-MRI tumor volume changes measured early during NICT can predict treatment response. Approach: DCE-MRI tumor volume reduction (TVR) was calculated in 64 TNBC at baseline, after 2 and 4 cycles of NICT and correlated with surgical pathology using ROC analysis. Results: DCE-MRI TVR after 2 cycles of NICT was able to predict pCR with AUC of 0.71 (95%CI:0.57-0.84) and after 4 cycles with AUC of 0.81 (95%CI:0.69-0.92). Impact: DCE-MRI tumor volume changes early during neoadjuvant immunochemotherapy can identify triple negative breast cancer patients with high/low likelihood of pathologic complete response, triaging them to appropriate management for de-escalation trials versus targeted therapies, avoiding unnecessary toxicity of ineffective treatment.